Company Profile
Cue Biopharma Inc Stock Price, News & Analysis
- Ticker:
- CUE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
27.01 USD (+1.35%)
Close
Last updated: August 6, 2026
116M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CUE closed up 1.35% at $27.01. No new same-company headline was identified in the current news window.
Company overview
Precision Immune Engineering Company
Cue Biopharma develops immune-disease therapies with the potential to produce functional cures. Its pipeline combines externally licensed assets with programs generated through the proprietary Immuno-STAT platform.
CUE-221 in Allergic Disease
CUE-221 is a late-stage anti-IgE asset exclusively licensed from Ascendant Health. It has a dual mechanism of action, is in Phase 2 development for allergic disease, and is planned for expansion into food allergy.
Portfolio Sourcing Strategy
Cue combines internally engineered Immuno-STAT programs with externally sourced clinical assets. The acquisition of rights to CUE-221 adds a later-stage program while CUE-401 and other platform candidates provide internally generated pipeline depth.
CUE-401 and Immune Tolerance
CUE-401 is a bifunctional IL-2 and TGF-β therapy designed to induce regulatory T-cell-mediated tolerance in autoimmune and inflammatory diseases. The program expands Cue’s approach from precision T-cell targeting into tolerance induction.
Future catalysts
An IND amendment for CUE-221 in food allergy is expected to be submitted to the FDA in the second half of 2026.
Results from Ascendant Health’s Phase 2 dose-ranging study of CUE-221 in chronic spontaneous urticaria in China are expected in the second half of 2026.
After reviewing the Chinese Phase 2 data, Cue plans to initiate a global Phase 2b study of CUE-221 in food allergy.
An IND for CUE-401 is expected in the second half of 2026, with a first-in-human Phase 1 study planned to begin before year-end.
Recent news
- 01
- 02
- 03
Cue Biopharma Announces $50.0 Million Private Placement
Source: Cue Biopharma Inc
- 04
- 05
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Source: Cue Biopharma Inc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cue Biopharma Inc (CUE)?
Cue Biopharma Inc (CUE) most recently closed at 27.01 USD, a +1.35% move versus the previous session.
What is the market cap of Cue Biopharma Inc (CUE)?
Cue Biopharma Inc currently has a market capitalization of 116M USD on BioPharmSignal.
What does Cue Biopharma Inc do?
Precision Immune Engineering Company Cue Biopharma develops immune-disease therapies with the potential to produce functional cures. Its pipeline combines externally licensed assets with programs generated through the proprietary Immuno-STAT platform. CUE-221 in Allergic Disease CUE-221 is a late-stage anti-IgE asset exclusively licensed from Ascendant...
On which exchange is CUE stock listed?
Cue Biopharma Inc (CUE) is associated with NASDAQ, United States, Biopharma.
What is CUE-221?
An IND amendment for CUE-221 in food allergy is expected to be submitted to the FDA in the second half of 2026.
Which conditions is Cue Biopharma Inc targeting with CUE-221?
An IND amendment for CUE-221 in food allergy is expected to be submitted to the FDA in the second half of 2026.
How does Cue Biopharma Inc describe recent progress with CUE-221?
An IND amendment for CUE-221 in food allergy is expected to be submitted to the FDA in the second half of 2026.
What is CUE-401?
The acquisition of rights to CUE-221 adds a later-stage program while CUE-401 and other platform candidates provide internally generated pipeline depth.